The Prostate Cancer Foundation Launches PSA Starring Actor Dax Shepard and First-Ever PCF Pushup Challenge as Part of Its ‘Do Blue’ Campaign to Kick-off Prostate Cancer Awareness Month
LOS ANGELES, Calif., September 4, 2018 – This year marks the 25th anniversary of the Prostate Cancer Foundation’s (PCF) efforts of advancing prostate cancer research. In honor of Prostate Cancer...Read More
Immunotherapy could offer hope for some men with aggressive prostate cancers
Original Press Release issued by: The Institute of Cancer Research, London Study finds that a subset of men with prostate cancer have ‘mismatch’ DNA repair defects in their tumours These men...Read More
The Prostate Cancer Foundation Announces Recipients of the 2018 PCF Young Investigator Awards
LOS ANGELES, Calif., August 28, 2018 – The Prostate Cancer Foundation (PCF) announced today that it has granted a total of $6 million to 29 promising early career scientists dedicated...Read More
The Prostate Cancer Foundation and the Movember Foundation Announce 2018 Challenge Awards Winners
SANTA MONICA, Calif., August 16, 2018 – The Prostate Cancer Foundation (PCF) and the Movember Foundation today announced four new Movember Foundation-PCF Challenge Award teams at some of the world’s leading academic research...Read More
The Prostate Cancer Foundation Appoints Christine Jones as Chief Operating Officer
SANTA MONICA, Calif., August 1, 2018 – The Prostate Cancer Foundation (PCF) today announced that Christine Jones has been appointed Chief Operating Officer effective immediately reporting to Jonathan W. Simons,...Read More
Genomic Landscape of Metastatic Prostate Cancer Unveiled in New Study
A comprehensive genetic analysis of metastatic prostate cancer has, for the first time, revealed a number of major ways in which abnormal alterations of the genome propel this aggressive form...Read More
NIH and Prostate Cancer Foundation launch large study on aggressive prostate cancer in African-American men
The largest coordinated research effort to study biological and non-biological factors associated with aggressive prostate cancer in African-American men has begun. The $26.5 million study is called RESPOND, or Research...Read More
FDA Approves Enzalutamide (Xtandi) for Non-Metastatic Castration-Resistant Prostate Cancer
July 13, 2018 – Today the U.S. Food and Drug Administration (FDA) approved enzalutamide (Xtandi) for the treatment of non-metastatic castration-resistant prostate cancer (non-metastatic CRPC). Non-metastatic CRPC is a clinical...Read More
Deadly Form of Advanced Prostate Cancer is Common, Calls for Distinct Treatment
Original article issued by UCSF News. A new study of prostate cancer in 202 men, whose cancers had spread and were resistant to standard treatment, found that a surprisingly large...Read More
Tumors Grown in the Lab Provide Insights on Rare Prostate Cancer
Original article issued by Weill Cornell Medicine. Growing miniature tumors from patient’s cells in the laboratory may help scientists personalize treatments for those with a rare form of prostate cancer,...Read More